Albert Labs’ Scientific and Clinical Advisory Boards will support the company’s efforts to develop its proprietary psychedelics-based medicine and conduct accelerated studies on UK patients suffering from cancer-related anxiety. VANCOUVER, BC, June 24, 2021 /CNW/ – Albert Labs (or the “Company”), an innovative psychedelic drug developer focused on accelerating access to approved psychedelics-based…


Previous articleExclusively-Natural Psychedelic Pharma Company, Filament Health, Lists on the NEO Exchange
Next articleWesana Health Partners with University of South Carolina